Aclarion, Inc. (Nasdaq: ACON, ACONW), a healthcare technology company using biomarkers and augmented intelligence to identify the source of chronic low back pain, announced the addition of Lanman Spinal Neurosurgery as a clinical site in its CLARITY trial. The Beverly Hills-based private practice is recognized for its expertise in complex spinal procedures, early adoption of innovative technologies, and high surgical volume. This inclusion marks a significant step in expanding the trial beyond academic medical centers into real-world clinical workflows.
The CLARITY trial is a prospective, randomized, multi-center study evaluating Nociscan in 300 patients undergoing surgical treatment for discogenic low back pain. The primary endpoint is change in back pain measured on a 100mm VAS Back at 12 months compared to baseline. The company anticipates an initial internal data readout and public disclosure of early interim results in Q4 2026.
“I have spent more than 25 years practicing spinal surgery in Beverly Hills, and my perspective is shaped not only by that experience, but also by having undergone multiple spine surgeries myself,” said Dr. Todd Lanman, neurosurgeon and founder of Lanman Spinal Neurosurgery. “We have made significant progress in moving beyond one-size-fits-all solutions for low back pain, driven by advances in technology and technique. Nociscan introduces a new layer of clarity by leveraging MR Spectroscopy to identify pain-generating discs in ways that standard MRI cannot. The CLARITY trial is particularly important because it is designed to evaluate how this technology can enhance clinical decision-making by more precisely identifying pain-generating discs. This ability to match the right procedure to the right patient is what moves the field forward.”
Ryan Bond, Chief Strategy Officer of Aclarion, noted, “Private practice spine surgeons play a critical role in treating the majority of patients suffering from chronic low back pain, and the inclusion of Lanman Spinal Neurosurgery reflects the growing demand for more precise, data-driven tools in everyday clinical practice. Dr. Lanman is widely recognized for his commitment to innovation and patient-centered care, and we are excited to partner with his team as we continue to expand CLARITY and generate the high-quality evidence needed to advance Nociscan.”
Chronic low back pain affects approximately 266 million people worldwide. Aclarion’s Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It uses magnetic resonance spectroscopy to quantify chemical biomarkers associated with disc pain, and when used with other diagnostic tools, demonstrates a 97% surgical success rate when all Nociscan-positive discs are treated.
For more information about the CLARITY trial, visit CLARITY Trial. To find a Nociscan center, view the site map here.
